For a healthier world

A clinical Phase 2 study in the United States has shown that Kinisoquin™ reduced hypercoagulability in cancer patients at high risk for thrombosis with an improved benefit/risk ratio. https://doi.org/10.1172/jci.insight.125851

A clinical Phase 2 study conducted by the NIH showed that Kinisoquin™ treatment attenuated blood coagulation, platelet aggregation and inducible tissue factor gene expression in adults with sickle cell disease. https://www.sciencedirect.com/science/article/pii/S2473952923006353

Quercis believes that drug development must be focused squarely on patient needs and that means ALL patient populations not just wealthy ones in first world countries. The humanitarian aspect of the Company is to look at treating global diseases in impoverished populations and to work with Governments and NGOs to improve healthcare in countries where they find it difficult to pay for development or production of new drugs to combat critical health threats such as Sickle Cell Disease. We plan to ensure that our next generation medications, available as capsules or tablets, drugs are made available to those less fortunate at massive discounts of 90% and more to less privileged communities around the world. Quercis plans to partner with Governments as well as NGOs to achieve this goal. Many wars are brought about by suffering of impoverished, less educated and oppressed populations who want to “break free” of an endless cycle of poverty, deplorable living conditions and lack of access to proper healthcare as a result of economic woes. Quercis is aware that it alone cannot solve all these complex problems, but we believe we can make a major contribution to health and peace by ensuring that the most vulnerable of human populations can access new orally available and affordable drugs.